Corporate news
EIPICO one of our top picks for 2026 , with a fair value of EGP 121.68/share.
The recent inauguration of “EIPICO 3” further strengthens our investment case, as it represents Egypt’s first facility dedicated to the production of biologics and biosimilars, and the first in both Egypt and the Middle East to integrate the manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms within a single facility. The plant is expected to produce 14 biologic products targeting immune-related diseases, with commercial production of the first two products already underway.
The project is expected to enhance EIPICO’s manufacturing capabilities, expand its high-value product portfolio, and support long-term revenue growth. Meanwhile, the company continues to strengthen its export footprint, with exports reaching EGP 3.0 billion (USD 63 million), representing 32% of total revenue of EGP 9.4 billion in FY2025. EIPICO currently exports to more than 60 countries and plans to enter 11 additional export markets by early 2027, further supporting its regional expansion strategy.
Walaa Mosalam - Prime Research
WMosalam@egy.primegroup.org